IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases
- PMID: 9010274
- PMCID: PMC1904539
- DOI: 10.1046/j.1365-2249.1997.d01-889.x
IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases
Abstract
IL-6, soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) levels were measured in sera and pleural effusions from 42 patients with metastatic carcinoma, non-Hodgkin's lymphoma, tuberculosis, cardiac failure and miscellaneous diseases. Pleural IL-6 levels measured by ELISA were very high in all patient groups (mean 34.8 +/- 15.3 ng/ml) without significant difference according to diseases. IL-6 was shown to be biologically active in a proliferative assay. Serum IL-6 levels were low (0.049 +/- 0.014 ng/ml) and did not correlate with pleural fluid levels. Pleural IL-6 levels correlated with the number of polymorphonuclear cells in pleural fluid (P < 0.03). Pleural sIL-6R levels (76 +/- 8 ng/ml) were always lower than serum levels (196 +/- 12 ng/ml; P < 0.0001) but correlated with them (P < 0.01). Pleural sIL-6R and albumin levels correlated (P < 0.01), suggesting a transudation of sIL-6R from the serum. Pleural sgp130 levels (10.9 +/- 1.0 ng/ml) were lower than serum levels (24.6 +/- 2.8 ng/ml; P < 0.002). After gel filtration of pleural fluid, the bulk of IL-6 (> 90%) was recovered in a 15,000-30,000 fraction, corresponding to the expected mol. wt of free IL-6. These results suggest a production and a sequestration of IL-6 in the pleural cavity in all studied conditions.
Similar articles
-
Soluble interleukin-6 receptor levels in pleural effusions.Respir Med. 1996 Jul;90(6):329-32. doi: 10.1016/s0954-6111(96)90127-4. Respir Med. 1996. PMID: 8759474
-
Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.Mediators Inflamm. 1999;8(6):277-86. doi: 10.1080/09629359990289. Mediators Inflamm. 1999. PMID: 10815616 Free PMC article.
-
Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.J Immunol. 1998 Dec 1;161(11):6347-55. J Immunol. 1998. PMID: 9834125
-
[Soluble IL-6 receptors].Postepy Hig Med Dosw. 1998;52(2):133-8. Postepy Hig Med Dosw. 1998. PMID: 9640977 Review. Polish.
-
The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.Biochim Biophys Acta. 2002 Nov 11;1592(3):323-43. doi: 10.1016/s0167-4889(02)00325-7. Biochim Biophys Acta. 2002. PMID: 12421676 Review.
Cited by
-
Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.Oncotarget. 2019 Nov 5;10(60):6456-6465. doi: 10.18632/oncotarget.27290. eCollection 2019 Nov 5. Oncotarget. 2019. PMID: 31741710 Free PMC article.
-
A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells.Front Immunol. 2023 Mar 30;14:1157697. doi: 10.3389/fimmu.2023.1157697. eCollection 2023. Front Immunol. 2023. PMID: 37063842 Free PMC article.
-
A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting.Front Immunol. 2024 Jul 24;15:1404373. doi: 10.3389/fimmu.2024.1404373. eCollection 2024. Front Immunol. 2024. PMID: 39114667 Free PMC article.
-
A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.Clin Exp Immunol. 2006 Jan;143(1):125-31. doi: 10.1111/j.1365-2249.2005.02960.x. Clin Exp Immunol. 2006. PMID: 16367943 Free PMC article.
-
Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity.Front Immunol. 2022 Feb 11;13:846235. doi: 10.3389/fimmu.2022.846235. eCollection 2022. Front Immunol. 2022. PMID: 35222439 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources